GW Pharmaceuticals PLC- (NASDAQ:GWPH) had its price target dropped by research analysts at Oppenheimer to $222.00 in a note issued to investors on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target suggests a potential upside of 102.91% from the company’s previous close.
GWPH has been the topic of several other reports. BidaskClub raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Friday, November 1st. ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. HC Wainwright initiated coverage on GW Pharmaceuticals PLC- in a research report on Wednesday, October 30th. They issued a “buy” rating and a $170.00 price target for the company. Bank of America reiterated a “buy” rating and issued a $218.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, September 25th. Finally, Morgan Stanley lifted their price target on GW Pharmaceuticals PLC- to $238.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. GW Pharmaceuticals PLC- currently has a consensus rating of “Buy” and a consensus price target of $198.00.
Shares of GWPH stock opened at $109.41 on Wednesday. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00. The company has a current ratio of 8.31, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03. The stock’s 50-day moving average price is $122.70 and its 200-day moving average price is $154.23. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of -10.36 and a beta of 2.28.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative return on equity of 23.44% and a negative net margin of 26.80%. The firm had revenue of $72.04 million for the quarter, compared to analysts’ expectations of $37.28 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. The business’s revenue was up 2096.3% compared to the same quarter last year. As a group, research analysts predict that GW Pharmaceuticals PLC- will post -3.53 EPS for the current fiscal year.
In other GW Pharmaceuticals PLC- news, insider Douglas B. Snyder sold 3,756 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $13.88, for a total transaction of $52,133.28. Following the completion of the transaction, the insider now owns 79,164 shares in the company, valued at $1,098,796.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Douglas B. Snyder sold 5,424 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $13.04, for a total value of $70,728.96. Following the transaction, the insider now owns 73,740 shares of the company’s stock, valued at approximately $961,569.60. The disclosure for this sale can be found here. 3.60% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the business. Tamarack Advisers LP purchased a new stake in shares of GW Pharmaceuticals PLC- in the third quarter valued at approximately $2,876,000. D.A. Davidson & CO. boosted its holdings in shares of GW Pharmaceuticals PLC- by 11.4% in the third quarter. D.A. Davidson & CO. now owns 4,024 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 413 shares during the period. River & Mercantile Asset Management LLP boosted its holdings in shares of GW Pharmaceuticals PLC- by 116.0% in the third quarter. River & Mercantile Asset Management LLP now owns 135,000 shares of the biopharmaceutical company’s stock valued at $15,518,000 after purchasing an additional 72,500 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of GW Pharmaceuticals PLC- by 28.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 101,194 shares of the biopharmaceutical company’s stock valued at $11,640,000 after purchasing an additional 22,481 shares during the period. Finally, Gainplan LLC purchased a new stake in shares of GW Pharmaceuticals PLC- in the third quarter valued at approximately $345,000. Institutional investors and hedge funds own 82.89% of the company’s stock.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Further Reading: What is the quiet period?
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.